BrightSpring (BTSG) Q2 2026 earnings review
Specialty Mix and Acquisitions Fuel a Strong Beat-and-Raise
BrightSpring delivered an exceptionally strong Q2 2026, posting 23% YoY revenue growth to $3.87B and a 44% surge in Adjusted EBITDA. The company successfully completed the divestiture of its Community Living business in Q1, allowing it to aggressively deleverage to 2.15x (down from 4.16x at FY24 year-end). While overall pharmacy script volumes remained completely flat, an aggressive mix shift toward high-margin specialty and infusion drugs drove a 28% increase in gross profit per script. Fueled by these structural improvements and the rapid integration of Amedisys/LHC home health branches, management raised full-year 2026 guidance across all key metrics.
🐂 Bull Case
Pharmacy Solutions EBITDA outpaced revenue growth (44% vs 22%), driven by aggressive expansion in Limited Distribution Drugs (LDDs) and specialty infusions. Gross profit per script jumped to $27.50 from $21.54 a year ago.
The successful integration of 107 Amedisys and LHC branches drove a 54% YoY increase in Home Health average daily census, pushing Provider Services revenue up 30% to $466M.
🐻 Bear Case
Total pharmacy prescriptions dispensed were flat YoY at 10.84M. The company is relying entirely on price and mix-shift for top-line pharmacy growth, which elevates concentration risk around specialty therapies.
Management has previously cited ~$356M in total 2026 revenue headwinds from the Inflation Reduction Act (IRA), which continues to heavily pressure the legacy Home & Community pharmacy sub-segment.
⚖️ Verdict: 🟢
Bullish. The company is executing flawlessly on its two main strategic pivots: shifting pharmacy to high-margin specialty drugs and scaling the provider segment via accretive M&A. Accelerated deleveraging significantly derisks the balance sheet.
Key Themes
Specialty Mix Shift Supercharges Unit Economics
The Pharmacy Solutions segment continues to be the undisputed growth engine. While script volume was flat at 10.84M, revenue per script accelerated significantly, growing 22% YoY to $314.20. More importantly, gross profit per script surged 28% to $27.50. This confirms management's narrative from prior quarters: winning exclusive and ultra-narrow Limited Distribution Drugs (LDDs) and driving brand-to-generic conversions is transforming the segment's profitability profile.
Home Health Integration Driving Scale
The Provider Services segment grew revenue 30% YoY to $466M, and EBITDA grew 33% to $75M. The primary driver is the rapid integration of the Amedisys/LHC branch acquisitions. Home Health Care average daily census spiked 54% to 46,448 patients. The fact that EBITDA growth outpaced revenue growth indicates BrightSpring is successfully centralizing functions like patient intake to drive margin expansion on the acquired assets.
Rapid Deleveraging Accomplished
Following the $811M net proceeds from the Community Living divestiture in Q1, BrightSpring used Q2 to further fortify its balance sheet. The company executed a $300M paydown on its First Lien Facility, which also secured interest rate refinancings resulting in forward interest savings. Leverage collapsed to 2.15x from 2.27x in Q1 (and down from 4.16x at the end of FY24). This hits management's long-term target of 2.0x-2.5x well ahead of schedule.
Flat Script Volumes Expose Growth Dependency
Despite a massive 22% jump in Pharmacy segment revenue, actual prescriptions dispensed were completely flat YoY (10.844M vs 10.851M). While management previously cited the intentional exit of uneconomic contracts, zero volume growth contradicts the overarching narrative of market share expansion. It forces the company to rely exclusively on price realization and mix-shift toward high-cost specialty drugs to drive the top line.
IRA Headwinds Limit Upside in Core Pharmacy
The macro policy environment continues to act as a governor on growth. In prior quarters, management explicitly guided for a ~$356M revenue headwind in 2026 resulting from the Inflation Reduction Act (IRA), split between the Home & Community and Specialty/Infusion sub-segments. While mix-shift is currently overpowering this drag, any slowdown in new LDD pipeline approvals could leave the company exposed to these structural regulatory impacts.
AI and Automation Offsetting Operational Costs
BrightSpring's margin expansion (EBITDA +44% vs Revenue +23%) is heavily supported by back-office tech investments. Management previously highlighted a 20+ person internal AI team deploying tools like automated patient intake processing and AI agents capable of parsing complex, 5-inch thick infusion patient packets in seconds. These innovations are critical for offsetting the lower margin profile of the recently acquired Amedisys branches.
Other KPIs
Accelerating. Gross profit grew 31.5% YoY, vastly outpacing the 23.0% top-line growth. This highlights tremendous operating leverage, driven primarily by favorable brand-to-generic conversions and procurement scale within the Pharmacy segment.
Accelerating significantly from just $9 million in Q2 2025. This massive flow-through to the bottom line reflects lower interest expenses from aggressive debt paydowns and the shedding of the lower-margin Community Living business.
Guidance
Accelerating. Management raised the full-year guide from the previous range of $14.725B-$15.225B. The new midpoint ($15.26B) represents approximately 18% YoY growth compared to FY25 (excluding the divested Community Living business).
Accelerating. Raised from the prior $795M-$825M range. This represents massive 32.8% to 36.8% YoY growth. The upward revision validates that the integration of the Amedisys and LHC assets (expected to contribute ~$35M in Adjusted EBITDA) and pharmacy margin efficiencies are tracking ahead of schedule.
Accelerating. The guidance was raised from the previous range of $12.85B-$13.3B, implying 15.3% to 17.9% YoY growth. This is a strong signal of confidence in the continued execution of the Specialty and Infusion strategy despite recognized IRA headwinds.
Stable to Accelerating. The bottom end of the range was lifted from $1.875B, narrowing the target to an implied 29.7% to 31.4% YoY growth rate. Driven almost entirely by the home health census expansion.
Key Questions
Underlying Volume Growth
With Q2 script volumes flat YoY, at what point do the 'uneconomic contract exits' fully lap, and what is the normalized baseline organic script growth expectation for 2027?
Capital Allocation Shift
Leverage has plummeted to 2.15x, well within the long-term target of 2.0x-2.5x. With the balance sheet now fully repaired, will BrightSpring shift capital allocation away from debt paydown and toward larger M&A or accelerated share repurchases?
Margin Ceiling in Pharmacy
Gross profit per script jumped 28% YoY. How much of this was driven by one-time brand-to-generic conversions versus sustainable structural mix shifts toward LDDs, and where is the ceiling for this metric?